World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0002073281
Reproduction Date:

Title: Anthracycline  
Author: World Heritage Encyclopedia
Language: English
Subject: Zorubicin, Pirarubicin, Aclarubicin, Epirubicin, Trabectedin
Publisher: World Heritage Encyclopedia


Daunorubicin, the prototypical anthracycline

Anthracyclines (or anthracycline antibiotics) are a class of drugs (CCNS or cell-cycle non-specific)[1] used in cancer chemotherapy derived from Streptomyces bacterium Streptomyces peucetius var. caesius.[2]

These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, bladder cancer, and lung cancers.

The anthracyclines are among the most effective anticancer treatments ever developed and are effective against more types of cancer than any other class of chemotherapeutic agents.[3][4][5] Their main adverse effect is cardiotoxicity, which considerably limits their usefulness. Use of anthracyclines has also been shown to be significantly associated with cycle 1 severe or febrile neutropenia.[6] Other adverse effects include vomiting.

The first anthracycline discovered was daunorubicin (trade name Daunomycin), which is produced naturally by Streptomyces peucetius, a species of actinobacteria. Doxorubicin (trade name Adriamycin) was developed shortly after, and many other related compounds have followed, although few are in clinical use.[3]


Available agents include:

Mechanism of action

Anthracyclines have four mechanisms of action:

  1. Inhibition of DNA and RNA synthesis by intercalating between base pairs of the DNA/RNA strand, thus preventing the replication of rapidly growing cancer cells.[7]
  2. Inhibition of topoisomerase II enzyme, preventing the relaxing of supercoiled DNA and thus blocking DNA transcription and replication. Some sources say that topoisomerase II inhibitors prevent topoisomerase II from turning over which is needed for dissociation of topoisomerase II from its nucleic acid substrate. In other words, topoisomerase II inhibitors stabilise the topoisomerase II complex after it has broken the DNA chain. This leads to topoisomerase II mediated DNA-cleavage, producing DNA breaks.[8] The binding of topoisomerase II inhibitor prevents DNA repair by ligase.[9][10]
  3. Iron-mediated generation of free oxygen radicals that damage the DNA, proteins and cell membranes.[7]
  4. Induction of histone eviction from chromatin that deregulates DNA damage response, epigenome and transcriptome.[11]


Anthracyclines can cause cardiotoxicity. This cardiotoxicity may be caused by many factors, which may include inhibition and/or poisoning of topoisomerase-IIB in cardiomyocytes,[12] interference with the ryanodine receptors of the sarcoplasmic reticulum, free radical formation in the heart, or from buildup of metabolic products of the anthracycline in the heart. The cardiotoxicity often presents as ECG changes (especially change in the frequency of QRS complex) and arrhythmias, or as a cardiomyopathy leading to heart failure (sometimes presenting many years after treatment). This cardiotoxicity is related to a patient's cumulative lifetime dose. A patient's lifetime dose is calculated during treatment, and anthracycline treatment is usually stopped (or at least re-evaluated by the oncologist) upon reaching the maximum cumulative dose of the particular anthracycline.[13]

There exists evidence that the effect of cardiotoxicity increases in long-term survivors, from 2% after 2 years to 5% after 15 years.[14]

In addition to staying below the cumulative doses, various prevention measures may be employed by the oncologist in order to reduce the risk of cardiotoxicity. Cardiac monitoring are recommended at 3, 6, and 9 months. Other measures include the use of Dexrazoxane, the use of liposomal preparations of doxorubicin when appropriate, as well as the administration of doxorubicin over longer infusion rates:[13]

  • Dexrazoxane is a cardioprotectant that is sometimes used to reduce the risk of cardiotoxicity; it has been found to reduce the risk of anthracycline cardiotoxicity by about two-thirds, without affecting response to chemotherapy or overall survival.[15]
  • The liposomal formulations of daunorubicin and doxorubicin are less toxic to cardiac tissue than the non-liposomal form because a lower proportion of drug administered in the liposome form is delivered to the heart.[16]
  • Longer infusion rates will result in a reduced plasma level and a much lower left ventricular peak concentration.[13]

See also


  1. ^ Trevor A, Katzung B, Masters S. Pharmacology: Examination and Board Review. Chapter 54, "Anthracycilne Antibiotics." Accessed through on 1/25/13.
  2. ^ Fujiwara, A.; Hoshino, T.; Westley, J. W. (1985). "Anthracycline Antibiotics". Critical Reviews in Biotechnology 3 (2): 133.  
  3. ^ a b Weiss RB (December 1992). "The anthracyclines: will we ever find a better doxorubicin?". Semin. Oncol. 19 (6): 670–86.  
  4. ^ Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (June 2004). "Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity". Pharmacol. Rev. 56 (2): 185–229.  
  5. ^ Peng X, Chen B, Lim CC, Sawyer DB (June 2005). "The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine". Mol. Interv. 5 (3): 163–71.  
  6. ^ Lyman GH, Kuderer NM, Crawford J, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer.2011;117(9):1917-1927.
  7. ^ a b Takimoto CH, Calvo E. "Principles of Oncologic Pharmacotherapy" in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds) Cancer Management: A Multidisciplinary Approach. 11 ed. 2008.
  8. ^ Pommier, Y., Leo, E., Zhang, H., Marchand, C. 2010. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 17: 421-433.
  9. ^ Osheroff Neil, Eukaryotic Topoisomerase II: characterisation of enzyme turnover, 1986, The Journal of Biological CHemistry, vol. 261, no. 21, pp. 9944-9950
  10. ^ Peter Buhl Jensen et al., Different modes of anthracycline interaction with topoisomerase II: Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance, 1993, Biochemical Pharmacology, vol. 45, no. 10, pp. 2025-2035
  11. ^ Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, Nieuwland M, Ovaa H, Rottenberg S, van Tellingen O, Janssen J, Huijgens P, Zwart W, Neefjes J (2013). "Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin". Nature Communications 4: 1908.  
  12. ^ Zhang, S.; Liu, X.; Bawa-Khalfe, T.; Lu, LS.; Lyu, YL.; Liu, LF.; Yeh, ET. (2012). "Identification of the molecular basis of doxorubicin-induced cardiotoxicity.". Nature Medicine 18 (11): 1639–42.  
  13. ^ a b c Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. (2004). "Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity". Pharmacological Reviews 56 (2): 185–229.  
  14. ^ Kremer L, van Dalen E, Offringa M, Ottenkamp J, Voûte P (2001). "Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study". J Clin Oncol 19 (1): 191–6.  
  15. ^ van Dalen EC, Caron HN, Dickinson HO, Kremer LC (2008). Van Dalen, Elvira C, ed. "Cardioprotective interventions for cancer patients receiving anthracyclines".  
  16. ^ Forssen, E. A.; Tökes, Z. A. (1979). "In vitro and in vivo studies with adriamycin liposomes". Biochemical and Biophysical Research Communications 91 (4): 1295–1301.  

External links

  • Media related to at Wikimedia Commons. Beta-blockers, ACE inhibitors, or ARBs have been used as primary prevention of anthracyline cardiotoxicity with uncertain results. Serial echocardiographic studies show preserved LVEF but troponin leaks persist. (JACC Vol 64, No. 9, 2014)
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.